Our Pipeline Images Core Pro 1 Etigilimab

Etigilimab (MPH313)

For patients with advanced or metastatic solid tumors Etigilimab is an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). TIGIT is a next generation checkpoint receptor shown to block T-cell activation and the body’s natural anti-cancer immune response. Etigilimab is an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells with a goal of improving the activation and effectiveness of T-cell and NK cell anti-tumor activity.

quote

The TIGIT immune receptor is a promising new target for cancer immunotherapy. We welcome the opportunity to collaborate with Mereo to jumpstart the clinical assessment of etigilimab in clear cell ovarian cancer, which lacks effective treatment options once advanced."

Ross Barrett, Managing Director, Cancer Focus Fund

Clinical Status

Mereo completed a Phase 1a dose escalation clinical trial with Etigilimab in patients with advanced solid tumors and enrolled patients in a Phase 1b study in combination with nivolumab in selected tumor types.

23 patients were treated in the Phase 1a dose escalation study with doses up to 20 mg/kg Q2W. Tumor types included colorectal cancer, endometrial cancer, pancreatic cancer and other tumors. No dose limiting toxicities were observed. In the Phase 1b combination study, a total of ten patients, nine of whom had progressed on prior anti-PD-1/PD-L1 therapies were enrolled at doses of 3, 10, and 20 mg/kg. Eight patients were evaluable for tumor growth assessment, and all of these patients had progressed on PD-1/PD-L1 therapies with best responses including one patient with a partial response another with stable disease. These patients remained on study for up to 224 days. No dose limiting toxicities (DLTs) were observed and the most common related adverse events included fatigue, rash, and pruritis.

We initiated ACTIVATE, a Phase 1b/2 basket combination study of etigilimab in combination with nivolumab in select recurrent advanced / metastatic solid tumors.

Early results are highly encouraging, with promising interim efficacy, safety, and biomarker data.

Efficacy Safety Biomarker Data
  • Among 15 patients in the efficacy analysis set, there was:
    • One complete response in the cervical cancer cohort
    • One partial response in one of the ovarian cancer patients
    • Four additional cases of stable disease in ovarian cancer, cervical cancer, and uveal melanoma.
  • The combination of etigilimab and nivolumab has been safe and well tolerated, with no new safety signals.
  • The most common treatment-related adverse events were skin reactions, observed in seven patients. None of these reactions required treatment with systemic steroids.
  • There was one case of immune diabetes mellitus
  • A positive trend was observed between baseline PVR expression and clinical benefit including in the absence of PD-L1 expression in the efficacy analysis population.
  • Clinical benefit also occurred in tumor types with historically low response rates to anti-PD-1/PDL-1 antibodies.

 

Continued evaluation of the combination of Etigilimab with an anti-PD-1 antibody is supported by these data

Etigilimab news

Image
Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors
30 November 2021

Mereo BioPharma today reported promising interim efficacy, safety, and biomarker data on patients from ACTIVATE, a Phase 1b/2 study of its anti-TIGIT antibody, etigilimab, in combination with nivolumab in select recurrent advanced / metastatic solid tumors

Image
Mereo BioPharma to Hold Virtual R&D Day on Thursday, May 13, 2021
04 May 2021

Mereo BioPharma today announced it will host a virtual R&D day on Thursday, May 13, 2021 to review the Company’s etigilimab (Anti-TIGIT) program.

Image
Mereo Reports Interim Data from ACTIVATE Phase 1b/2 Study of Etigilimab Mereo Reports Interim Data from ACTIVATE Phase 1b/2 Study of Etigilimab
30 November 2021

Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors

One complete response, one partial response and four cases of stable disease observed among 15 patients in the efficacy analysis set

Etigilimab was well tolerated with a favorable safety profile

Conference call today at 8:30am ET